Novel, non-intensive treatment options in older MDS/ AML patients planned for allografting, with the goal of down-staging the underlying disease and bridging time to transplantation, are presently being developed. 5-azacytidine and decitabine (DAC) are of particular interest, as they can be given repetitively, with very limited nonhematologic toxicity and result in responses both in MDS and AML even at low doses. We describe 15 consecutive patients (median age 69 years, range 60-75 years) with MDS (n ¼ 10) or AML (n ¼ 5) who all received first-line treatment with DAC and subsequent allografting (from sibling donor in four patients, unrelated donor in 11) after reduced-intensity conditioning with the FBM regimen. Successful engraftment was attained in 14/15 patients, all of whom achieved a CR, with a median duration of 5 months (range 1 þ to 51 þ ). Six of these 14 patients are alive (4 with complete donor chimerism), 8 have died either from relapse (n ¼ 4) or treatment-related complications while in CR (n ¼ 4). We conclude that allografting after low-dose DAC and subsequent conditioning with FBM is feasible, with no unexpected toxicities and appears as a valid alternative to standard chemotherapy ('InDACtion instead of induction') in elderly patients with MDS/AML.
Introduction
Patients with AML (and often also with high-risk myelodysplastic syndromes (MDS)) scheduled for allo-SCT receive standard induction chemotherapy first, with the goal of attaining a CR. This disease control is usually necessary to bridge the time needed for identifying an unrelated donor in case no sibling donor is available, although CR is no absolute prerequisite for successful allografting following reduced-intensity conditioning. 1 However, prior induction chemotherapy may result in toxicities and prolonged cytopenia, and in related severe infections like invasive aspergillosis prohibiting or compromising subsequent allografting. Thus, innovative approaches are urgently needed to bridge time to transplantation. 2 Recently, non-intensive treatment with low-dose azanucleosides has been developed for older patients with higher-risk MDS. 3, 4 Low-dose azanucleosides show a particularly interesting activity in inducing cytogenetic remissions in MDS patients with chromosome 7 abnormalities and other poor-risk cytogenetics. 5, 6 They therefore represent a milder treatment alternative to induction chemotherapy in older patients who are eligible for allografting after reduced-intensity conditioning, provided this novel treatment does not compromise the outcome of the allografting.
Patients and methods
Between February 1998 and May 2007, the 15 patients were treated with low-dose decitabine (DAC), after obtaining written informed consent, within a phase II multicenter study of DAC (PCH97-19) in advanced MDS (n ¼ 3), 7 the MDS phase III Study 06011 of the EORTC/German MDS Study Group (n ¼ 7) 8 and the multicenter phase II study 00331 of older patients with AML (n ¼ 5). 9 All patients received DAC over 72 h every 6 weeks as described for MDS. 7 MDS responses were scored according to IWG 2000 criteria, AML responses according to CALGB criteria. Of the five AML patients treated in the 00331 study, one (UPN 5) received ATRA during the second course of DAC as per protocol. One patient with AML and initial hyperleukocytosis (UPN 8) received cytoreduction with hydroxyurea prior to start of DAC. All patients received reduced-toxicity conditioning according to the Fludarabine, BCNU and melphalan (FBM) protocol 1, 2 prior to allografting. Stem cells were taken either from matched sibling (n ¼ 4) or unrelated donor (n ¼ 11), including four with HLA mismatch. All studies were approved by the local Ethics Committee, and were performed in accordance with the Principles of the Declaration of Helsinki.
Chimerism analysis
Quantification of chimerism was performed on bone marrow and/or peripheral blood samples before and after transplantation by FISH or variable number of tandem repeat studies as described earlier. 1 
Results
We report a single-center experience of 15 consecutive patients aged 60 years or older (median age 69 years, range 60-75 years) all receiving first-line treatment with low-dose DAC for MDS (n ¼ 10) or AML (n ¼ 5) followed by allografting after reduced-intensity conditioning according to the FBM protocol. Patient characteristics are given in Table 1 . Seven patients had poor cytogenetics. The median number of DAC courses given was five (range 1-23), with CR/PR as best response in 5/1 patients, hematologic improvement in two, stable or progressive disease in six and one patient, respectively. Allografting was either performed as a consolidation at the time of best response to DAC (n ¼ 5) or as salvage for relapsed (n ¼ 9) or refractory disease (n ¼ 1). Four patients received second line treatment (polo-like kinase inhibitor in two, low-dose melphalan and hydroxyurea each in one) before allografting. The median time from start of DAC to allografting in the entire group was 349 days (range, 79-1318 days). The disease stage of the patients at the time of transplantation and thus the timing of transplantation was variable, and dependent on the choice of time point as described above. Median BM blast percentage before initiation of conditioning was 24 (range 0-490%) in the entire group, nine (range 0-30%) in the five patients transplanted at the time of best response to DAC, and 38 (13-490%) in the 10 patients transplanted for relapsed/refractory disease.
After conditioning with FBM patients were transplanted with PBSC either from matched sibling (n ¼ 4) or unrelated donor (n ¼ 11), including four with HLA mismatch. One patient (having received both BM and PBSC) died due to infection on day þ 13, thus before engraftment. The other 14 patients engrafted, with no unexpected toxicities noted, and achieved a CR. Eight of 10 informative patients showed complete donor chimerism on days þ 30 and þ 100 ( Table 2 ). Median duration of CR was 5 months (range 1 þ to 51 þ ). Acute GVHD occurred in 5/14 patients (grade III in two of them), chronic GVHD in five (subsequent to DLI in two of them). Eight of 14 patients who engrafted have died either following relapse (n ¼ 4) or treatment-related complications while in CR (n ¼ 4): one patient with varicella zoster virus encephalitis, 11 one with generalized aspergillosis including pneumonia and two with cardiac failure. Six patients (four with MDS, two with AML), 
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Abbreviations: CyA=cyclosporine A; LD=low dose; NA=not applicable; PLKI=polo-like kinase inhibitor (phase I study); rel.=relapse; Tx=transplantation; prot.=according to study protocol.
In case of missing cytogenetics due to lack of metaphases (n.m.), IPSS was assigned based only on bone marrow blasts and cytopenias. The tMDS in patient 7 was subsequent to radio-chemotherapy for breast cancer, in patient 9 subsequent to scleroderma treated with cyclophosphamide. a no metaphases, abnormality detected by FISH. b flt-3 mutational status, performed on DNA from bone marrow cells as described 10 showed wild-type configuration. 12 of HLA upregulation by the DNA demethylating agent DAC in myeloid leukemic blasts and the in vivo observation of upregulation by DAC of cancer testis antigens, such as NY-ESO-1 and a number of MAGE genes. 13, 14 Thus pretreatment with low doses of an azanucleoside, not primarily aiming at a merely cytotoxic antileukemic effect like with low-dose cytarabine (LD-AraC), may act also through modulation of gene expression in the malignant cells, rendering them more immunogenic in the process. Giralt and co-workers had already implemented DAC in a conditioning regimen for allografting, with the rationale of increasing the graft vs leukemia effect and reported promising results. 15 However, the use of azanucleosides is based on continued treatment, as time to best response is often prolonged for these drugs. It is unclear which time point is optimal for stopping this treatment and performing allografting. As the older patients often have no sibling donor, bridging time to donor identification is very important.
2 With non-intensive therapy, patients may receive outpatient management and thus need not lose their fitness during this period.
In the present analysis, we show that reduced-intensity conditioning by FBM protocol 16 and allografting in older patients with AML/MDS following DAC treatment is very feasible, and no unexpected toxicities have occurred. Particularly the GVHD rate was not higher than expected. This is a strong theoretical concern as one may reason that azanucleosides may upregulate genes non-selectively, thus also on normal, 'bystander' cells and promote GVHD. Interestingly, microarray studies show that the transcriptome of untransformed cells is changed only to a minor degree by these drugs compared to malignant cells. 17 The good feasibility is supportive of the use of low-dose azanucleosides also after allogeneic transplantation, either at hematologic relapse 18, 19 or even pre-emptively in highrisk patients. 20 DAC pretreatment can induce improvement or even remission of MDS/AML with negligible nonhematopoietic toxicity, thus effectively bridging the time of donor search prior to allografting. In the present series, the 'downstaging' that is desirable prior to transplantation was not an absolute prerequisite for favorable outcome, as also With low-dose azanucleoside treatment, not achievement of a high CR rate but disease control with acceptable side effects is the primary goal. As treatment even with multiple courses of low-dose DAC is unlikely to be curative without subsequent allografting, this option should be explored more often in these patients. Response to DAC and pre-transplant riskassessment (comorbidities, performance status, etc.) will likely be major determinants of optimal timing of allografting in this setting. A prospective phase II trial of the EBMT is planned to address these questions.
